The PARASAIL study Patient reported outcomes from the Canadian real world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction
29 April 2017 (08:30 - 17:30)
Organised by:
Abstract
Slides
About the speaker
Novartis Pharmaceuticals Canada Inc, Dorval (Canada)
49 More presentations in this session
Access the full session
The Event
Heart Failure 2017 - 4th World Congress on Acute Heart Failure
29 April 2017
08:30 CET
You may be interested in
Congress Session
Congress Presentation
Congress Presentation
